As the case for AI adoption strengthens, thanks to growing evidence and regulatory clearances, more laboratories are beginning to deploy computational pathology. The AI-enabled platform has – quite rightfully – been posited as a future-proof means of bringing these applications into the workflow. It’s hardly surprising that we’re seeing a tranche of perspectives on what it is and what it should do. But how should laboratories make sense of these differing views to chart their path to success? Chief Product Officer Nathan Buchbinder unpacks three key considerations in this contributed article.